PUBLISHER: Allied Market Research | PRODUCT CODE: 1193270
PUBLISHER: Allied Market Research | PRODUCT CODE: 1193270
The global surgical glue market was valued at $2,340.71 million in 2021, and is projected to reach $4,614.85 million by 2031, registering a CAGR of 7.0% from 2022 to 2031.
Surgical glue is made of two components contained in separate vials; a freeze dried concentrate of clotting proteins, mainly fibrinogen, Factor XIII and fibronectin (the sealant) and freeze dried thrombin (the catalyst). The first component is reconstituted with an aprotinin solution that inhibits tissue fibrinolysis. The second component (thrombin) is dissolved with calcium chloride that is available in 500 I.U. concentration. Indications for the use of human fibrin sealant are numerous and present in all surgical branches. It is also effective in preventing local hemorrhagic complications after inguinal hernia repair in patients with concurrent coagulation disorders.
The global surgical glue market is anticipated to show significant market growth during the forecast period, owing to increase in geriatric population, increase in number of surgical procedures performed, and increase in incidence of wounds and injuries. Furthermore, increase in number of road accidents, increase in awareness regarding surgical glue and increase in prevalence of chronic diseases are considerably contributing toward the market growth. However, high cost of surgical glues and availability of alternate products and unpopularity of minimally invasive surgeries are negatively impacting the market growth. Conversely, the high growth potential in emerging countries offers lucrative opportunities for growth of the market.
The global surgical glue market is segmented on the basis of product, application, end user, and region. By product, the market is classified into natural and synthetic & semi-synthetic. By application, it is classified into central nervous system (CNS) surgeries, general surgeries, cardiovascular surgeries, orthopedic surgeries, cosmetic surgeries, ophthalmic surgeries, urological surgeries, pulmonary surgeries, and others. By end user, it is classified into hospitals, ambulatory surgery centers, and others. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).
Major companies profiled in the report include Artivion, Inc., B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company, Cardinal Health, Integra Lifesciences Corporation, Johnson & Johnson, Medtronic plc, Ocular Therapeutix Inc., and OptMed, Inc.
Key Benefits For Stakeholders
By End user
By Product
By Application
By Region